ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
艾格里房產
74.80
-0.3400
-0.45%
盤後:
74.80
0.0000
0.00%
19:14 EDT
成交量:
106.07萬
成交額:
7,973.05萬
市值:
85.97億
市盈率:
43.69
高:
75.89
開:
75.14
低:
74.69
收:
75.14
52周最高:
79.65
52周最低:
67.58
股本:
1.15億
流通股本:
1.08億
量比:
0.80
換手率:
0.98%
股息:
3.05
股息率:
4.08%
每股收益(TTM):
1.71
每股收益(LYR):
1.79
淨資產收益率:
3.48%
總資產收益率:
2.33%
市淨率:
1.51
市盈率(LYR):
41.72
資料載入中...
總覽
公司
新聞
公告
再鼎醫藥公佈Zocilurtatug Pelitecan(前稱ZL-1310)最新一期臨牀數據, 顯示其成為同類首創用於小細胞肺癌的靶向DLL3 ADC的潛力,並啓動全球三期註冊研究
美通社
·
10/25
默沙東PD-1+ADC殺瘋了
氨基观察
·
10/24
再生元終止開發一款雙靶點CAR-T;葛蘭素史克BCMA ADC藥物Blenrep獲批上市
氨基观察
·
10/24
華東醫藥、恆瑞新藥在華上市,GSK重磅ADC在美上市
医药经济报
·
10/24
Blenrep 強勢迴歸:FDA再次批准GSK的BCMA ADC藥物Blenrep用於治療骨髓瘤
Minhua笔记
·
10/24
財經早報:美國宣佈制裁俄羅斯兩大石油公司 基金10月參與定增熱情升温丨2025年10月23日
新浪证券
·
10/23
114億美元!信達與武田達成合作 腫瘤藥市場能否迎「王炸」?
21世纪经济报道
·
10/22
百利天恆(688506.SH):注射用BL-M24D1(ADC)藥物臨牀試驗獲批准
智通财经
·
10/21
Macrogenics, Inc.盤中異動 急速上漲5.45%
市场透视
·
10/20
全球首個無進展生存期、總生存期雙獲益 科倫博泰TROP2 ADC實現肺癌二線治療突破
每日经济新闻
·
10/20
ESMO炸場!中國ADC「一哥」亮劍
智通财经
·
10/20
復宏漢霖PD-L1 ADC HLX43獲美國FDA孤兒藥資格認定
南方财经网
·
10/20
健訊Daily|《醫療器械管理法》立法調研在京開展;翰森ADC藥物賣給羅氏
21世纪经济报道
·
10/20
ESMO大會本週重磅開幕;超 4款國產新藥出海,翰森、奧賽康、維立志博科倫 ADC新藥獲批上市 Insight新藥週報
动脉网
·
10/19
港股上市僅半年!映恩生物擬回A股科創板上市 股價最高漲近5倍,業績連虧三年半
深圳商报·读创
·
10/19
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
prnewswire
·
10/18
科倫博泰HER2 ADC藥物獲批用於治療乳腺癌 該靶點國內已有多款藥物上市
每日经济新闻
·
10/17
千億巨頭大動作
中国基金报
·
10/17
兩天4家上市藥企官宣BD交易,兩筆潛在最高金額超過15億美元
澎湃新闻
·
10/17
港股異動 | 先聲藥業(02096)漲超4% 先聲再明新型ADC候選藥物SIM0505完成Ⅰ期臨牀美國首例患者入組
智通财经
·
10/17
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/ADC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房產","latestPrice":74.8,"timestamp":1761336000000,"preClose":75.14,"halted":0,"volume":1060738,"hourTrading":{"tag":"盘后","latestPrice":74.8,"preClose":74.8,"latestTime":"19:14 EDT","volume":29322,"amount":2193332.55,"timestamp":1761347668391},"delay":0,"floatShares":108366822,"shares":114934390,"eps":1.712089,"marketStatus":"休市中","change":-0.34,"latestTime":"10-24 16:00:00 EDT","open":75.14,"high":75.885,"low":74.69,"amount":79730461.93273,"amplitude":0.015904,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.712089,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1761552000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":75.14,"dividendRate":0.040829,"preHourTrading":{"tag":"盘前","latestPrice":75.14,"preClose":75.14,"latestTime":"08:02 EDT","volume":8,"amount":588.95,"timestamp":1761307341238},"postHourTrading":{"tag":"盘后","latestPrice":74.8,"preClose":74.8,"latestTime":"19:14 EDT","volume":29322,"amount":2193332.55,"timestamp":1761347668391},"volumeRatio":0.8038027670558262,"impliedVol":0.1989,"impliedVolPercentile":0.2},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":108366822,"roa":"2.33%","roe":"3.48%","lyrEps":1.793039,"volumeRatio":0.8038027670558262,"shares":114934390,"dividePrice":3.054,"high":75.885,"amplitude":0.015904,"preClose":75.14,"low":74.69,"week52Low":67.58,"pbRate":"1.51","psRate":"12.48","week52High":79.65,"institutionHeld":0.9901,"latestPrice":74.8,"eps":1.712089,"divideRate":0.040829,"volume":1060738,"delay":0,"ttmEps":1.712089,"open":75.14,"prevYearClose":70.45,"prevWeekClose":75.06,"prevMonthClose":71.04,"prevQuarterClose":71.04,"fiveDayClose":75.06,"twentyDayClose":71.26,"sixtyDayClose":71.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2025-10-31","symbol":"ADC","amount":0.262,"announcedDate":"2025-10-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-31","defaultRemindTime":1761917400000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-14","payableDate":"2025-10-31","currency":"USD","dateTimestamp":1761883200000,"payDate":"2025-11-14"},{"date":"2025-10-21","symbol":"ADC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":1.05,"defaultRemindTime":1761076800000,"name":null,"time":"盤後","dateTimestamp":1761019200000,"actualEps":1.03},{"date":"2025-09-30","symbol":"ADC","amount":0.256,"announcedDate":"2025-09-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-30","defaultRemindTime":1759239000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-14","payableDate":"2025-09-30","currency":"USD","dateTimestamp":1759204800000,"payDate":"2025-10-14"},{"date":"2025-08-29","symbol":"ADC","amount":0.256,"announcedDate":"2025-08-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-29","defaultRemindTime":1756474200000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-15","payableDate":"2025-08-29","currency":"USD","dateTimestamp":1756440000000,"payDate":"2025-09-15"},{"date":"2025-07-31","symbol":"ADC","amount":0.256,"announcedDate":"2025-07-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-31","defaultRemindTime":1753968600000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-14","payableDate":"2025-07-31","currency":"USD","dateTimestamp":1753934400000,"payDate":"2025-08-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2016-01-05","value":0.465,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-15","value":0.465,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-15","value":0.48,"currency":"USD"},{"executeDate":"2016-09-28","recordDate":"2016-09-30","paymentDate":"2016-10-14","value":0.48,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2017-01-03","value":0.495,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.381,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.381,"analysts":21,"updateTime":1752206400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2025-10-24","current":43.689318,"percent":0.792345,"low":31.539495,"twenty":37.639342,"median":41.220151,"eighty":44.656944,"high":53.261716,"avg":41.272428,"sd":4.471176,"marketCap":8621592904},"quantilePoints":[{"date":"2020-10-30","current":38.164301,"twenty":31.975443,"median":37.733323,"eighty":43.037844,"marketCap":3447190528},{"date":"2020-11-06","current":38.797606,"twenty":31.975443,"median":37.935059,"eighty":43.037844,"marketCap":3504393786},{"date":"2020-11-13","current":41.26934,"twenty":31.975443,"median":38.046028,"eighty":43.037844,"marketCap":3727653105},{"date":"2020-11-20","current":40.039622,"twenty":31.975443,"median":38.167733,"eighty":43.037844,"marketCap":3616578817},{"date":"2020-11-27","current":40.506914,"twenty":31.975443,"median":38.310136,"eighty":43.037844,"marketCap":3658787046},{"date":"2020-12-04","current":40.580698,"twenty":31.975443,"median":38.471704,"eighty":43.037844,"marketCap":3665451504},{"date":"2020-12-11","current":40.230228,"twenty":31.975443,"median":38.545534,"eighty":43.037844,"marketCap":3633795331},{"date":"2020-12-18","current":39.344831,"twenty":31.975443,"median":38.676992,"eighty":43.037844,"marketCap":3553821844},{"date":"2020-12-24","current":39.762935,"twenty":31.975443,"median":38.782235,"eighty":43.037844,"marketCap":3591587102},{"date":"2020-12-31","current":40.937316,"twenty":31.975443,"median":38.892751,"eighty":43.037844,"marketCap":3697663047},{"date":"2021-01-08","current":45.450661,"twenty":31.975443,"median":39.008592,"eighty":43.047885,"marketCap":4105330986},{"date":"2021-01-15","current":44.653159,"twenty":31.975443,"median":39.245492,"eighty":43.22631,"marketCap":4033296550},{"date":"2021-01-22","current":45.359718,"twenty":31.975443,"median":39.341757,"eighty":43.313411,"marketCap":4097116533},{"date":"2021-01-29","current":44.212433,"twenty":31.975443,"median":39.41667,"eighty":43.4163,"marketCap":3993488046},{"date":"2021-02-05","current":46.262155,"twenty":31.975443,"median":39.41667,"eighty":43.554978,"marketCap":4178629185},{"date":"2021-02-12","current":45.520618,"twenty":31.975443,"median":39.41667,"eighty":43.618647,"marketCap":4111649797},{"date":"2021-02-19","current":43.859591,"twenty":31.975443,"median":39.41667,"eighty":43.642628,"marketCap":4007933303},{"date":"2021-02-26","current":44.718497,"twenty":31.977009,"median":39.430911,"eighty":43.756513,"marketCap":4086420942},{"date":"2021-03-05","current":44.656157,"twenty":31.975443,"median":39.41667,"eighty":43.796506,"marketCap":4080724259},{"date":"2021-03-12","current":46.594043,"twenty":31.975443,"median":39.41667,"eighty":43.856021,"marketCap":4257810284},{"date":"2021-03-19","current":46.240217,"twenty":31.975443,"median":39.41667,"eighty":43.889974,"marketCap":4225477299},{"date":"2021-03-26","current":46.69811,"twenty":31.977009,"median":39.430911,"eighty":43.995818,"marketCap":4267319985},{"date":"2021-04-01","current":47.239256,"twenty":31.977009,"median":39.430911,"eighty":44.083322,"marketCap":4316770432},{"date":"2021-04-09","current":47.1005,"twenty":31.975443,"median":39.41667,"eighty":44.146464,"marketCap":4304090831},{"date":"2021-04-16","current":47.627771,"twenty":31.975443,"median":39.41667,"eighty":44.201737,"marketCap":4352273317},{"date":"2021-04-23","current":49.334461,"twenty":31.975443,"median":39.41667,"eighty":44.216631,"marketCap":4508232419},{"date":"2021-04-30","current":48.814129,"twenty":31.975443,"median":39.41667,"eighty":44.274005,"marketCap":4460683913},{"date":"2021-05-07","current":44.881383,"twenty":31.975443,"median":39.41667,"eighty":44.314742,"marketCap":4499986938},{"date":"2021-05-14","current":44.377456,"twenty":31.975443,"median":39.41667,"eighty":44.249425,"marketCap":4449461218},{"date":"2021-05-21","current":44.026621,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4414285084},{"date":"2021-05-28","current":44.830352,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4494870410},{"date":"2021-06-04","current":45.665977,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4578653566},{"date":"2021-06-11","current":45.646841,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4576734868},{"date":"2021-06-18","current":47.246871,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4737160278},{"date":"2021-06-25","current":48.748389,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4887708512},{"date":"2021-07-02","current":48.211648,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4833892628},{"date":"2021-07-09","current":49.210395,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4934031046},{"date":"2021-07-16","current":49.93058,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5006239701},{"date":"2021-07-23","current":50.956505,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5109102975},{"date":"2021-07-30","current":53.056971,"twenty":31.977009,"median":39.430911,"eighty":44.230599,"marketCap":5165308396},{"date":"2021-08-06","current":52.598062,"twenty":31.977009,"median":39.430911,"eighty":44.296692,"marketCap":5120631744},{"date":"2021-08-13","current":52.520401,"twenty":31.977009,"median":39.430911,"eighty":44.412506,"marketCap":5113071079},{"date":"2021-08-20","current":52.718085,"twenty":31.977009,"median":39.430911,"eighty":44.625208,"marketCap":5132316407},{"date":"2021-08-27","current":52.209754,"twenty":31.977009,"median":39.430911,"eighty":44.658936,"marketCap":5082828422},{"date":"2021-09-03","current":52.675724,"twenty":31.977009,"median":39.430911,"eighty":44.712504,"marketCap":5128192408},{"date":"2021-09-10","current":49.555141,"twenty":31.977009,"median":39.430911,"eighty":44.74795,"marketCap":4824391169},{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826},{"date":"2025-05-30","current":42.698147,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8169607171},{"date":"2025-06-06","current":42.411197,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8114703897},{"date":"2025-06-13","current":42.927706,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8213529790},{"date":"2025-06-20","current":43.220395,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8269531129},{"date":"2025-06-27","current":41.894687,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8015878004},{"date":"2025-07-03","current":41.30357,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7902777259},{"date":"2025-07-11","current":40.735409,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7794068777},{"date":"2025-07-18","current":41.234702,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7889600473},{"date":"2025-07-25","current":42.319373,"twenty":37.604201,"median":40.725789,"eighty":44.606841,"marketCap":8097134849},{"date":"2025-08-01","current":42.372392,"twenty":37.604201,"median":40.742491,"eighty":44.606841,"marketCap":7873129491},{"date":"2025-08-08","current":43.918584,"twenty":37.604201,"median":40.752858,"eighty":44.633348,"marketCap":8160424292},{"date":"2025-08-15","current":42.901923,"twenty":37.604201,"median":40.790693,"eighty":44.633348,"marketCap":7971520467},{"date":"2025-08-22","current":44.019656,"twenty":37.604201,"median":40.820493,"eighty":44.633348,"marketCap":8179204204},{"date":"2025-08-29","current":43.199192,"twenty":37.604201,"median":40.894276,"eighty":44.633348,"marketCap":8026755504},{"date":"2025-09-05","current":42.806797,"twenty":37.595885,"median":40.935905,"eighty":44.639951,"marketCap":7953845256},{"date":"2025-09-12","current":43.841294,"twenty":37.604201,"median":40.969944,"eighty":44.633348,"marketCap":8146063183},{"date":"2025-09-19","current":42.527363,"twenty":37.604201,"median":41.008406,"eighty":44.633348,"marketCap":7901924321},{"date":"2025-09-26","current":41.962551,"twenty":37.639342,"median":41.035693,"eighty":44.633348,"marketCap":7796977752},{"date":"2025-10-03","current":42.027951,"twenty":37.639342,"median":41.102705,"eighty":44.633348,"marketCap":7809129460},{"date":"2025-10-10","current":41.974442,"twenty":37.639342,"median":41.115788,"eighty":44.633348,"marketCap":7799187153},{"date":"2025-10-17","current":44.322871,"twenty":37.639342,"median":41.17126,"eighty":44.633348,"marketCap":8235543942},{"date":"2025-10-24","current":44.544295,"twenty":37.639342,"median":41.220151,"eighty":44.656944,"marketCap":8621592904}],"updateTime":1761487408972},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2578526897","title":"再鼎醫藥公佈Zocilurtatug Pelitecan(前稱ZL-1310)最新一期臨牀數據, 顯示其成為同類首創用於小細胞肺癌的靶向DLL3 ADC的潛力,並啓動全球三期註冊研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2578526897","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578526897?lang=zh_tw&edition=fundamental","pubTime":"2025-10-25 00:10","pubTimestamp":1761322200,"startTime":"0","endTime":"0","summary":"有11例患者曾接受过DLL3双特异性抗体治疗。共有5例患者因治疗相关不良事件终止治疗,均发生于较高的剂量组。鉴于小细胞肺癌侵袭性强、治疗选择有限,临床对新疗法存在迫切需求。Zoci最新的1期研究结果显示,在患者尤其是是伴有不良预后因素的患者中,显示出快速且持续的缓解,这进一步为其作为潜在的差异化靶向DLL3 ADC提供了最新临床证据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4806457_ZH06457_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4531","BK4231","BK4588","09688","BK1574","BK4585","BK4080","BK4548","ZLAB","BK1588","BK4139","BK4526","LU2488822045.USD","ADC","BK1161"],"gpt_icon":0},{"id":"2578572996","title":"默沙東PD-1+ADC殺瘋了","url":"https://stock-news.laohu8.com/highlight/detail?id=2578572996","media":"氨基观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578572996?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 19:55","pubTimestamp":1761306933,"startTime":"0","endTime":"0","summary":"在这种背景下,默沙东率先探索IO+ADC协同路径。/ 02 /IO+ADC领头羊在PD-1+ADC这个赛道上,默沙东绝对是领头羊。默沙东此前在ASCO上也明确表示,将重点布局K药+ADC组合,以应对专利到期带来的市场压力。PD-1抑制剂主要激活免疫反应,但并非所有患者都敏感;而ADC可直接杀伤肿瘤细胞,同时释放抗原,进一步增强免疫应答。目前默沙东拥有业内最大的免疫肿瘤临床研究项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200637a472b40c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200637a472b40c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4239.USD","BK4023","LU2468319806.SGD","LU1093756168.USD","BK4516","SG9999002232.USD","LU1291159041.SGD","IE000M9KFDE8.USD","IE00B1BXHZ80.USD","LU0861579265.USD","LU1066051225.USD","LU1169590202.USD","BK4007","LU2361045086.USD","IE00BJT1NW94.SGD","LU0320765489.SGD","IE0009355771.USD","LU2023250504.SGD","LU0070302665.USD","SG9999014575.USD","LU0203345920.USD","SG9999013999.USD","LU0211331839.USD","LU1037948541.HKD","ADC","LU0122379950.USD","BK4550","MRK","LU2089984988.USD","IE00B4R5TH58.HKD","SG9999002224.SGD","LU1941712348.USD","IE00BFTCPJ56.SGD","LU2461242641.AUD","LU1069347547.HKD","LU1035773651.USD","LU1023059063.AUD","LU1061106388.HKD","LU0265550946.USD","LU1917777945.USD","LU1037948897.HKD","SG9999014567.USD","SG9999015341.SGD","BK4534","LU0965509010.AUD","LU1066053197.SGD","LU2361044949.HKD","LU0985320562.USD","PD","LU1934455194.USD"],"gpt_icon":0},{"id":"2577157955","title":"再生元終止開發一款雙靶點CAR-T;葛蘭素史克BCMA ADC藥物Blenrep獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2577157955","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577157955?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 19:55","pubTimestamp":1761306933,"startTime":"0","endTime":"0","summary":"葛兰素史克ADC药物死而复生。/ 03 /海外药闻1)再生元终止开发一款双靶点CAR-T10月23日,再生元决定放弃从2seventy bio收购的双靶点CAR-T疗法bbT369,该药物正在处于早期研究的剂量递增阶段中,用于评估治疗复发/难治性B细胞非霍奇金淋巴瘤患者。2)葛兰素史克BCMA ADC药物Blenrep获批上市10月23日,GSK宣布,美国FDA已批准其BCMA ADC药物Blenrep上市,联合硼替佐米和地塞米松,用于治疗至少接受过两种既往疗法的复发或难治性多发性骨髓瘤成年患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200649a6cc0bc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200649a6cc0bc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC","BK4532","BK4588","BK4022","BK4585","CAR","LU1829250122.USD","BK4007","GSK.UK","GSK","BK4230","BK4231","BK4080"],"gpt_icon":0},{"id":"2577152425","title":"華東醫藥、恆瑞新藥在華上市,GSK重磅ADC在美上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2577152425","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577152425?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 18:31","pubTimestamp":1761301916,"startTime":"0","endTime":"0","summary":"华东医药重磅新药获批上市10月24日,国家药监局官网显示,华东医药全资子公司杭州中美华东制药申报的1类新药马来酸美凡厄替尼片获批上市,适应症为:用于表皮生长因子受体21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。GSK重磅ADC在美国获批上市当地时间10月23日,葛兰素史克宣布,BCMA ADC玛贝兰妥单抗已获得FDA批准上市。这也是全球首个获批上市的BCMA ADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024184004a6cbe5b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024184004a6cbe5b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","01276","BK4080","GSK","BK4585","BK4588","ADC","LU1829250122.USD","GSK.UK","BK4231","BK4532"],"gpt_icon":1},{"id":"2577787515","title":"Blenrep 強勢迴歸:FDA再次批准GSK的BCMA ADC藥物Blenrep用於治療骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2577787515","media":"Minhua笔记","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577787515?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 12:35","pubTimestamp":1761280554,"startTime":"0","endTime":"0","summary":"Blenrep 于 2020 年首次获得加速批准,作为多发性骨髓瘤 的五线单药疗法。虽然这两项试验可能解决了疗效方面的担忧,但也引发了有关 Blenrep 相关眼部毒性的进一步质疑,最终导致 FDA 的咨询委员会投票反对批准其用于GSK寻求的适应症:与 BVd 联合用于二线 MM 治疗。尽管 FDA 最终没有听从其咨询委员会的建议,允许 Blenrep 重新上市,但该机构并未批准该 ADC 的预期适应症,而是将其重新推后到三线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024124759a471de19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024124759a471de19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GSK","BK4585","BK4080","BK4231","BK4532","LU1829250122.USD","GSK.UK","ADC","BK4588"],"gpt_icon":0},{"id":"2577346540","title":"財經早報:美國宣佈制裁俄羅斯兩大石油公司 基金10月參與定增熱情升温丨2025年10月23日","url":"https://stock-news.laohu8.com/highlight/detail?id=2577346540","media":"新浪证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577346540?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 07:44","pubTimestamp":1761176640,"startTime":"0","endTime":"0","summary":"超3000名“专业选手”如何调仓?最牛选手单只标的浮盈超300%. 美国总统特朗普当地时间10月22日表示,他认为现在与俄罗斯总统普京会面“不合适”,所以取消了和普京在布达佩斯的会面。美股全线重挫,美国对俄施加新制裁,黄金巨震,原油飙升。 数据显示,截至目前,A股23家上市公司发布2025年三季度分红方案。 美国财政部当地时间22日宣布,将对俄罗斯两大石油公司实施制裁。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/y/2025-10-23/doc-infuvrav7279741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443549.SGD","LU1127390331.HKD","IE00BK4W5L77.USD","BK4534","BK4543","ADC","LU0127658192.USD","LU2237443895.HKD","BK4141","IE00BFSS8Q28.SGD","LU1699723380.USD","LU0289960550.SGD","BK4532","399300","LU2361044949.HKD","BK4581","LU2108987350.USD","LU0079474960.USD","BK4614","LU1852331112.SGD","LU1242518931.SGD","LU1880398471.USD","LU2237443382.USD","SG9999002224.SGD","BK4612","LU1934455863.HKD","IE0004445015.USD","LU1804176565.USD","LU2361045086.USD","IE0004445239.USD","BK4512","SG9999002232.USD","BK4573","LU2087621335.USD","LU1037948897.HKD","IE00BN29S564.USD","LU2361044865.SGD","BK4080","IPO","IE00B775H168.HKD","SGXZ31699556.SGD","BK4579","USJW.SI","SG9999014914.USD","IE00BK4W5M84.HKD","SG9999014880.SGD","IE00BJJMRX11.SGD","159982"],"gpt_icon":1},{"id":"2577133132","title":"114億美元!信達與武田達成合作 腫瘤藥市場能否迎「王炸」?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577133132","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577133132?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 12:21","pubTimestamp":1761106896,"startTime":"0","endTime":"0","summary":"继辉瑞与三生制药之后,创新药商业拓展(BD)再迎百亿美元重磅交易。10月22日,信达生物宣布与武田制药达成重磅全球战略合作,此次合作旨在联合信达生物在肿瘤免疫(IO)与抗体偶联药物(ADC)的创新研发实力,及武田制药全球肿瘤药物开发的深厚经验,加速信达生物两款后期在研药物的全球开发进程,同时武田制药将获得一款早期研发项目的选择权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510223540990549.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510223540990549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2242644610.SGD","LU2097828714.EUR","LU2097828557.USD","LU0502904849.HKD","LU1969619763.USD","BK1583","MSS","BK4113","LU2097828631.EUR","ADC","LU2488822045.USD","BK4080","BK1161","LU2097828474.EUR","BK1589","BK4231","LU2097828805.USD","01801","LU0455707207.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2577874885","title":"百利天恆(688506.SH):注射用BL-M24D1(ADC)藥物臨牀試驗獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2577874885","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577874885?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 22:52","pubTimestamp":1761058321,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百利天恒(688506.SH)公告,公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药注射用BL-M24D1(ADC)的药物临床试验获得批准。BL-M24D1是公司自主研发的偶联了新一代毒素的ADC药物,是与BL-B16D1和BL-M17D1出自同一小分子技术平台、与BL-B16D1和BL-M17D1共享同一“连接子+毒素”平台的ADC药物,其适应症为复发或难治性血液系统恶性肿瘤和晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BL","BK4023","BK4080","91194","LU1815336091.USD","LU0757428866.USD","ADC","BK4231","688506","BK0239"],"gpt_icon":0},{"id":"2577256815","title":"Macrogenics, Inc.盤中異動 急速上漲5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577256815","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577256815?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 21:34","pubTimestamp":1760967281,"startTime":"0","endTime":"0","summary":"北京时间2025年10月20日21时34分,Macrogenics, Inc.股票出现异动,股价大幅拉升5.45%。Macrogenics, Inc.股票所在的生物技术行业中,整体涨幅为0.38%。其相关个股中,Replimune Group, Inc.、Celcuity Inc.、Azitra Inc涨幅较大,Azitra Inc、Genprex, Inc.、Scisparc Ltd.较为活跃,换手率分别为1036.94%、317.31%、111.67%,振幅较大的相关个股有Ethzilla Corporation C/Wts 06/11/2025、Rapt Therapeutics, Inc.、Corbus Pharmaceuticals Holdings, Inc.,振幅分别为22.92%、16.37%、14.75%。Macrogenics, Inc.公司简介:Macrogenics Inc是一家生物技术公司,专注于发现和开发用于治疗癌症的基于抗体的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020213441a6c3e193&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020213441a6c3e193&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4231","BK4080","MGNX","BK4139","ADC"],"gpt_icon":0},{"id":"2576528328","title":"全球首個無進展生存期、總生存期雙獲益 科倫博泰TROP2 ADC實現肺癌二線治療突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2576528328","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576528328?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 20:42","pubTimestamp":1760964129,"startTime":"0","endTime":"0","summary":"破解EGFR突变非小细胞肺癌(NSCLC)的EGFR-TKI耐药,是新一代疗法的共同课题。近日,科伦博泰在2025年欧洲肿瘤内科学会年会上,公布了TROP2ADC芦康沙妥珠单抗(sac-TMT)的一项III期临床研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510203538976632.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510203538976632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4080","ADC"],"gpt_icon":0},{"id":"2576851949","title":"ESMO炸場!中國ADC「一哥」亮劍","url":"https://stock-news.laohu8.com/highlight/detail?id=2576851949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576851949?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 20:18","pubTimestamp":1760962692,"startTime":"0","endTime":"0","summary":"本次ESMO大会上,TROP2 ADC芦康沙妥珠单抗有两项III期临床研究入选LBA并作口头报告,均为支持新适应症上市的关键临床数据。OptiTROP-Lung04旨在评估芦康沙妥珠单抗单药对比培美曲塞联合铂类用于经EGFR-TKI治疗失败的EGFR突变NSCLC患者的有效性和安全性。这一积极结果,使其成为全球首个针对二线EGFR突变型NSCLC人群实现PFS与OS双重获益的ADC药物,填补了该治疗领域长期存在的关键空白。胃癌是全球发病率第五、死亡率第四的恶性肿瘤,而中国更是胃癌高发国家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","LU0196878994.USD","BK4080","06990","BK4231","BK1161"],"gpt_icon":0},{"id":"2576000514","title":"復宏漢霖PD-L1 ADC HLX43獲美國FDA孤兒藥資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2576000514","media":"南方财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576000514?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 08:47","pubTimestamp":1760921250,"startTime":"0","endTime":"0","summary":"南方财经10月20日电,复宏汉霖宣布,公司创新型程序性死亡-配体1(PD-L1)抗体偶联药物(ADC)注射用HLX43已获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定(OrphanDrugDesignation,ODD),用于胸腺上皮肿瘤(ThymicEpithelialTumors,TETs)的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510203538123857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","LU1169589451.USD","LU1169590202.USD","02696","ADC","BK4231","BK1161","BK4023","PD"],"gpt_icon":0},{"id":"2576000275","title":"健訊Daily|《醫療器械管理法》立法調研在京開展;翰森ADC藥物賣給羅氏","url":"https://stock-news.laohu8.com/highlight/detail?id=2576000275","media":"21世纪经济报道","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576000275?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 08:02","pubTimestamp":1760918537,"startTime":"0","endTime":"0","summary":"政策动向市场监管总局、国家药监局调研组在京开展《医疗器械管理法》立法调研10月17日消息,市场监管总局副局长束为和国家药监局副局长徐景和率调研组10月15日在京就《医疗器械管理法》草案开展立法调研。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510203538112195.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510203538112195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","03692","BK1589","BK1222","BK4231","BK1574","BK1191","BK1583","09996","BK4080","09997","BK1100"],"gpt_icon":0},{"id":"2576825878","title":"ESMO大會本週重磅開幕;超 4款國產新藥出海,翰森、奧賽康、維立志博科倫 ADC新藥獲批上市 Insight新藥週報","url":"https://stock-news.laohu8.com/highlight/detail?id=2576825878","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576825878?lang=zh_tw&edition=fundamental","pubTime":"2025-10-19 20:05","pubTimestamp":1760875500,"startTime":"0","endTime":"0","summary":"ESMO大会本周开幕,据Insight数据库统计,10月12日至18日,全球86款创新药研发有新进展,其中1款获批上市,5款申报上市,2款首次启动III期临床,19款启动临床,26款申报临床。境外部分,本周23款药物研发有推进,包括1款首次启动III期临床,9款首次启动临床,8款首次获批临床。此外,诺华公布了伊普可泮Ⅲ期最终分析结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102001380797372ce2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102001380797372ce2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B2B36J28.USD","LU0320765992.SGD","LU0058720904.USD","SG9999001440.SGD","IE00BJJMRZ35.SGD","BK4566","LU1983299246.USD","ADC","BK4534","IE0002141913.USD","LU0868494617.USD","LU1057294990.SGD","LU2242652126.USD","IE0009355771.USD","LU0889565916.HKD","BK4533","AMGN","BK4231","LU0109394709.USD","LU1571399168.USD","BK4599","INAQU","LU2089984988.USD","LU2242646821.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU2468319806.SGD","BK4585","BK4139","BK4080","BK4581","IE00B4R5TH58.HKD","LU2112291526.USD","BK4588","LU0289739699.SGD"],"gpt_icon":0},{"id":"2576302354","title":"港股上市僅半年!映恩生物擬回A股科創板上市 股價最高漲近5倍,業績連虧三年半","url":"https://stock-news.laohu8.com/highlight/detail?id=2576302354","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576302354?lang=zh_tw&edition=fundamental","pubTime":"2025-10-19 09:17","pubTimestamp":1760836645,"startTime":"0","endTime":"0","summary":"10月17日晚间,港股映恩生物(证券简称:映恩生物-B,代码:09606)发布内幕消息,公司拟回A股上市。公告显示,2025年10月17日,映恩生物董事会决议公司拟发行将于上海证券交易所科创板上市并以人民币买卖的普通股(“建议发行人民币股份”)。建议发行人民币股份取决于及受限于市场状况、董事会的进一步批准、股东于本公司股东大会上的批准及必要监管机构的批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510193537964627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","ADC","BK4231"],"gpt_icon":0},{"id":"2576048378","title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576048378?lang=zh_tw&edition=fundamental","pubTime":"2025-10-18 22:46","pubTimestamp":1760798760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that at the 2025 European Society for Medical Oncology Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative breast cancer was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration and was included in the priority review and approval process.","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","BK4225","ADC.AU","BC","BK7095","HR","BK4203","BK4080","BK4190"],"gpt_icon":0},{"id":"2576105754","title":"科倫博泰HER2 ADC藥物獲批用於治療乳腺癌 該靶點國內已有多款藥物上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576105754","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576105754?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 23:57","pubTimestamp":1760716632,"startTime":"0","endTime":"0","summary":"10月17日晚,科伦博泰(06990.HK)公告称,公司靶向人类表皮生长因子受体2(HER2)的抗体偶联药物(ADC)博度曲妥珠单抗(亦称A166,即“舒泰莱”)获国家药品监督管理局(NMPA)批准用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌(BC)患者。这是科伦博泰截至目前获批上市的第二款ADC药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510173537603516.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537603516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2576608140","title":"千億巨頭大動作","url":"https://stock-news.laohu8.com/highlight/detail?id=2576608140","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576608140?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 15:53","pubTimestamp":1760687618,"startTime":"0","endTime":"0","summary":"【导读】翰森制药与罗氏达成重磅合作,潜在交易总额达15.3亿美元中国基金报记者卢鸰“中国最牛医药夫妻档”之一的钟慧娟又有大动作。10月17日早间,翰森制药公告称,将其在研的CDH17靶向抗体偶联药物(ADC)HS-20110在大中华区以外的全球权益,授权给知名跨国医药巨头罗氏的子公司。该产品目前正在中国和美国开展用于治疗结直肠癌(CRC)及其他实体瘤的全球I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510173537251427.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537251427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03692","BK4213","BK4231","LU0456854461.SGD","CRC","BK1191","BK4080","ADC","BK1583","LU0266512127.USD","BK1589"],"gpt_icon":0},{"id":"2576085465","title":"兩天4家上市藥企官宣BD交易,兩筆潛在最高金額超過15億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576085465","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576085465?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 14:39","pubTimestamp":1760683180,"startTime":"0","endTime":"0","summary":"两天内,已有4家国内上市药企官宣了4笔对外授权交易,涉及ADC、双抗、CAR-T疗法、等热门赛道。10月17日早间,翰森制药集团有限公司(翰森制药,3692.HK)公告称,已与罗氏就HS-20110签署许可协议,翰森制药授予罗氏在全球范围内(不含中国内地、香港、澳门和台湾)推进HS-20110开发及商业化的独家权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510173537194055.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537194055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03692","BK4230","BK1589","CAR","BK4231","BK1583","BK4080","BK4022","BK1191","ADC"],"gpt_icon":0},{"id":"2576706595","title":"港股異動 | 先聲藥業(02096)漲超4% 先聲再明新型ADC候選藥物SIM0505完成Ⅰ期臨牀美國首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2576706595","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576706595?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 10:05","pubTimestamp":1760666724,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,先声药业再涨超4%,截至发稿,涨3.47%,报13.42港元,成交额8999.23万港元。消息面上,据先声药业官微消息,10月16日,先声药业旗下的抗肿瘤创新药公司先声再明与致力于癌症创新药开发的临床阶段美国生物制药公司NextCure, Inc.宣布,SIM0505用于晚期实体瘤患者的Ⅰ期临床试验已完成首例美国患者给药。据介绍,SIM0505是由先声再明研发的一款靶向CDH6的新型ADC。其独特的结合表位对肿瘤抗原的亲和力高于同类候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK1583","BK1191","BK4080","02096","ADC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":182,"code":"91000000","status":"200"}]}}